ProImmune Conference Videos | ProImmune
ProImmune Videos
Mastering Immunity Europe 2016

Prof. Herman Waldmann

University of Oxford

"Short-term therapeutic intervention for the therapeutic harnessing of tolerance mechanisms"

Dr. Farnaz Fallah-Arani

UCB Pharma, UK

“Challenges to experimental design to test immunotherapeutic drugs to achieve clinically relevant results.”

Dr. Jeremy Fry

ProImmune Ltd., UK

“An integrated approach to managing immunogenicity risk and drug immune modulation.”

Dr. Bernd Schlereth

Covagen, Switzerland

“Special considerations in pharmacokinetic and immunogenicity assessment of bispecific antibody constructs”

Dr. Bernard Maillère

CEA, France

“Comprehensive analysis of pre-existing T cells specific to therapeutic proteins in healthy donors”

Prof. David Wraith

University of Bristol

“Antigen-specific tolerance induction: allergy, autoimmunity and anti-drug antibodies”

Dr. Peter Adler Wurtzen

ALK-Abelló, Denmark

“Immunological biomarkers in Allergy Immunotherapy”

Prof. Paul Moss

University of Birmingham

“Direct visualisation of antigen-specific CD4+ T cells: insights from HLA class II tetramers”

Prof. Ada Kruisbeek

DCPrime, The Netherlands

“Developing off-the-shelf dendritic cell based vaccines: pre-clinical and clinical observations”


Dr. Wei Xue

Roche Innovation Center Zurich, Switzerland

“Combination immunotherapy and vaccines in cancer”



Mastering Immunity 5 (2015)

Dr. Ethan Shevach


"Tregs -ready for the clinic"

Dr. Keith Knutson

Mayo Clinic, Jacksonville

“Vaccines for Prevention of Breast Cancer”

Prof. Jean Rommelaere

DKFZ, Germany

“Use of oncolytic parvoviruses in the treatment of malignant gliomas: a viro-immunotherapeutic approach”

Dr. Jeremy Fry


“An integrated approach to managing immunogenicity risk and drug immune modulation”

Dr. Xiaoying Chen

Pfizer, Inc.

“A Systems Pharmacology Approach to Immunogenicity – A multi-scale, Mechanistic Mathematical Model and Its Applications”

Prof. Armagan Kocer

University of Groningen

“Ion channel decorated liposomes: therapeutic potential and immunogenicity”

Prof. David Wraith

University of Bristol

“Switching off immunity: the mechanism of antigen-specific immunotherapy”

Prof. Julio Delgado

University of Utah

“Assessment of TNF-alpha antagonists and Anti-Drug Antibodies in the Clinical Laboratory”

Dr. Gene Olinger


“Development of a monoclonal antibody cocktail for Ebola virus therapy: convergence of plants, mice, and humans”


Prof. Lawrence Steinman

Stanford University

“Vaccines, adjuvants, and autoimmunity”



Mastering Immunogenicity 4 (2014)

Prof. Herman Waldmann

University of Oxford

"Tolerance can be induced in the adult immune system"

Prof. Arlene Sharpe

Harvard University

“T Cell Coinhibitory Pathways and Cancer Immunotherapy: Roles of the PD-1 pathway in controlling tolerance and tumor immunity”

Dr. Timothy Hickling

Pfizer, Inc.

“Contribution of ex vivo assays to immunogenicity risk assessment”

Dr. Sabine Zollner

CSL Behring

“Preclinical characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII under clinical development at CSL Behring”

Dr. Nades Palaniya

The Hospital for Sick Children, Toronto

“Targeting innate immune collectins and neutrophil extracellular traps (NETs) to regulate inflammatory diseases”

Dr. Joleen White

Biogen IDEC

“Evaluation of Peginterferon Beta-1a and Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Immunogenicity in Multiple Sclerosis”

Dr. Jeremy Fry


“Tools and Technologies for Immunogenicity Risk Management”

Dr. Bruce Hall

University of New South Wales

“Antigen specific CD4+CD25+Foxp3+Treg generated from natural Treg (nTreg)”

Dr. Amy Loercher


“ABIRISK Developments and Challenges: Perspectives from Year 2”


Dr. Susan Kirshner


“Therapeutic Proteins: Routes of Exposure and the risk of immunogenicity”



Mastering Immunogenicity 3 (2013)

Prof. David Wraith

University of Bristol

"Dealing with Unwanted Immunogenicity: The Design and Development of Tolerogenic T Cell Epitopes"

Dr. Florian Deisenhammer


“Drug Immunogenicity: Lessons Learnt from Interferon-beta”

Dr. Beth Chang


“XTEN in Blood Factor Engineering”

Dr. William Sanderson

University College London

“Phenotypic Structure of B Cell Subsets as a Tool for the Investigation for Immunogenicity”

Dr. Michael Cancro

University of Pennsylvania

“B Cell Selection and Survival: First Order Consideration for Immunogenicity”

Dr. Larry Kauver


“Antibody Repertoire Monitoring: Application to Anti-Drug Antibodies”

Dr. Jeremy Fry


“Mastering Immunogenicity: Tools and Technologies”

Dr. Samuel Pine


“Immunologic Endpoints for Guiding Biologic Drug Development”

Dr. Caroline Barelle

University of Aberdeen

“Shark VNAR Domains: Immunogenicity Determination in the Early Stages of Development Aids Candidate Selection for "First-Man" Studies”


Dr. Federico Mingozzi

University Pierre et Marie Curie

“Assessing and Modulating Immune Responses to AVV Vectors in Humans”



Mastering Immunogenicity 2 (2012)

Dr. Manoj Rajadhyaksha


"Working towards building a “Value Added Proposition” for Immunogenicity Prediction and Risk Management"

Prof. Bonnie Rup


“Understanding the problem of unwanted immunogenicity risk in biotherapeutic discovery and development: advances, gaps, opportunities”

Dr. Jeremy Fry


“Tools and technologies for comprehensive immunogenicity risk management”


Dr. Nikolai Schwabe


“Mastering Immunity: ProStorm™Cytokine Release Assay”

Dr. Bob DuBridge

Full Spectrum Genetics

“MapEng™ A Powerful, New Tool in the Engineering of Biobetter Therapeutics”


Best Practice Immunogenicity Risk Management (2012)

Dr. Tim Hikling


"Immunogenicity of biotherapeutics: Why do we care and where do we stand?"

Dr. Robin Thorpe

NIBSC Health Protection Agency

“CHMP Guidance on Unwanted Immunogencity: Best Practice Iummunogenicity Risk Management: Oxford 2012”

Dr. Katharina Steinitz

Baxter Innovations GmbH

“Identification of promiscuous FVIII-specific CD4+ T-cell epitopes in a humanized mouse model for hemophilia A”


Dr. Heather Hinton


“Pre-Clinical Risk Assesment Using Innovative Technologies”

Dr. David Ulaeto


“Therapeutic potential of a humanised antibody for the treatment of Venezuelan Equine Encephalitis Virus”